Monitor the effectiveness of the S-3 registration statement and any subsequent ATM sales disclosures. The pace and volume of share sales under the ATM will determine the actual dilution impact. Watch for clinical trial updates on the company's lead candidate as the only potential catalyst to offset dilution.
Price Chart
Executive Summary
ProKidney Corp. entered into an Open Market Sale Agreement with Jefferies LLC to establish an at-the-market (ATM) equity facility of up to $200 million, contingent on the effectiveness of its S-3 shelf registration filed the same day. The company has no approved products and no revenue, making this a potentially dilutive capital raise that could increase share count significantly.
Key Facts
- ProKidney entered into an Open Market Sale Agreement with Jefferies LLC for an ATM offering of up to $200 million in Class A common stock.
- The ATM facility is subject to the effectiveness of the S-3 shelf registration statement filed on October 29, 2026.
- Jefferies will receive up to 3.0% of gross proceeds as compensation.
- The company has no approved products and no revenue; net tangible book value was $222.8 million as of June 30, 2026.
- The ATM alone could increase share count by up to 63% at the current price of $1.52 per share.
- The S-3 shelf registers up to $650 million in securities total, including the $200 million ATM facility.
Financial Impact
Up to $200 million in potential equity issuance; at $1.52/share, this represents up to ~63% dilution relative to current shares outstanding.
Risk Factors
- Significant dilution risk if the ATM is fully utilized, potentially exceeding 60% of current shares outstanding.
- No approved products or revenue stream; the company is entirely dependent on clinical development success and capital markets access.
- The S-3 shelf also registers up to $650 million in total securities, leaving room for additional dilutive offerings beyond the ATM.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-438071 |
| Document: 0001193125-26-438071-index-headers.html | 0001193125-26-438071 |
| Document: 0001193125-26-438071-index.html | 0001193125-26-438071 |
| Document: 0001193125-26-438071.txt | 0001193125-26-438071 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 29, 2026 2d ago | 8-K | $1.51 | awaiting T+20 | awaiting T+20 | $1.29 (+14.24%) |
Oct 29, 2026 2d ago | S-3 | $1.51 | awaiting T+20 | awaiting T+20 | $1.29 (+14.24%) |
Oct 22, 2026 10d ago | Press Release | $1.43 | awaiting T+20 | awaiting T+20 | $1.29 (−9.44%) |
Aug 10, 2026 11w ago | 8-K | No price | awaiting T+20 | awaiting T+20 | No price |
Aug 10, 2026 11w ago | Press Release | $1.61 $1.85 | ▲ +14.91% | ▲ +15.97% | $1.29 (−19.57%) |
May 15, 2026 24w ago | 8-K | No price | awaiting T+20 | awaiting T+20 | No price |
May 15, 2026 24w ago | Press Release | $1.66 $1.67 | ▲ +0.60% | ▼ −1.52% | $1.29 (−21.99%) |
Apr 17, 2026 28w ago | DEFA14A | $2.10 $1.61 | ▼ −23.33% | ▼ −27.54% | $1.29 (−38.33%) |
Mar 18, 2026 32w ago | Press Release | $1.95 $2.18 | ▲ +11.79% | ▲ +4.17% | $1.29 (−33.59%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers